Physician profile
Edith Hergan
NPI 1326016726
$1,213.61
in general payments reported to CMS, 2019-2025
13 companies · $637 in 2025
The $637 reported for 2025 was more than what 82% of Addiction Medicine (Internal Medicine) providers received nationally (typical 2025 total: $124).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $53.42 · 2020: $16.16 · 2021: $111 · 2022: $108 · 2023: $75.54 · 2024: $212 · 2025: $637.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $925.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $924.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $398.41 | 2021-2025 | |
| Indivior INC. | $183.43 | 2019-2025 | Sublocade |
| Alkermes, INC. | $157.83 | 2019-2025 | Aristada, Vivitrol, Lybalvi |
| Takeda Pharmaceuticals U.S.A., INC. | $88.70 | 2025 | Trintellix |
| Braeburn INC. | $79.87 | 2024 | Brixadi |
| Janssen Pharmaceuticals, INC | $65.56 | 2025 | Spravato |
| E.R. Squibb & Sons, L.L.C. | $59.44 | 2025 | Cobenfy |
| Otsuka America Pharmaceutical, INC. | $49.37 | 2025 | Rexulti |
| Vanda Pharmaceuticals INC. | $44.41 | 2025 | Fanapt |
| Orexo US, INC. | $33.95 | 2024 | Zubsolv |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $21.11 | 2025 | Caplyta |
| Eisai INC. | $15.85 | 2021 | |
| Tms Neurohealth Centers INC. | $15.68 | 2025 | Tms Neurohealth Centers INC. |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edith Hergan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.